VARIDT 1.0: variability of drug transporter database

The absorption, distribution and excretion of drugs are largely determined by their transporters (DTs), the variability of which has thus attracted considerable attention. There are three aspects of variability: epigenetic regulation and genetic polymorphism, species/tissue/disease-specific DT abundances, and exogenous factors modulating DT activity. The variability data of each aspect are essential for clinical study, and a collective consideration among multiple aspects becomes crucial in precision medicine. However, no database is constructed to provide the comprehensive data of all aspects of DT variability. Herein, the Variability of Drug Transporter Database (VARIDT) was introduced to provide such data. First, 177 and 146 DTs were confirmed, for the first time, by the transporting drugs approved and in clinical/preclinical, respectively. Second, for the confirmed DTs, VARIDT comprehensively collected all aspects of their variability (23 947 DNA methylations, 7317 noncoding RNA/histone regulations, 1278 genetic polymorphisms, differential abundance profiles of 257 DTs in 21 781 patients/healthy individuals, expression of 245 DTs in 67 tissues of human/model organism, 1225 exogenous factors altering the activity of 148 DTs), which allowed mutual connection between any aspects. Due to huge amount of accumulated data, VARIDT made it possible to generalize characteristics to reveal disease etiology and optimize clinical treatment, and is freely accessible at: https://db.idrblab.org/varidt/ and http://varidt.idrblab.net/.

[1]  Sanjay K. Nigam,et al.  What do drug transporters really do? , 2014, Nature Reviews Drug Discovery.

[2]  K. To,et al.  Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat. , 2017, Lung cancer.

[3]  Jun Yan,et al.  METscout: a pathfinder exploring the landscape of metabolites, enzymes and transporters , 2012, Nucleic Acids Res..

[4]  Huijun Sun,et al.  Combination of dihydromyricetin and ondansetron strengthens antiproliferative efficiency of adriamycin in K562/ADR through downregulation of SORCIN: A new strategy of inhibiting P‐glycoprotein , 2018, Journal of cellular physiology.

[5]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[6]  M. Schwab,et al.  DNA Methylation of ADME Genes , 2016, Clinical pharmacology and therapeutics.

[7]  Feng Zhu,et al.  Simultaneous Improvement in the Precision, Accuracy, and Robustness of Label-free Proteome Quantification by Optimizing Data Manipulation Chains* , 2019, Molecular & Cellular Proteomics.

[8]  Xiaofeng Li,et al.  ANPELA: analysis and performance assessment of the label-free quantification workflow for metaproteomic studies , 2019, Briefings Bioinform..

[9]  Tingting Fu,et al.  Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics , 2017, Nucleic Acids Res..

[10]  P. Sexton,et al.  Drug transporters in drug efficacy and toxicity. , 2012, Annual review of pharmacology and toxicology.

[11]  Byunghan Lee,et al.  Deep learning in bioinformatics , 2016, Briefings Bioinform..

[12]  Alan F. Scott,et al.  OMIM.org: leveraging knowledge across phenotype–gene relationships , 2018, Nucleic Acids Res..

[13]  Andrew R. Leach,et al.  ChEMBL: towards direct deposition of bioassay data , 2018, Nucleic Acids Res..

[14]  Andrea Bernini,et al.  A Computational Approach From Gene to Structure Analysis of the Human ABCA4 Transporter Involved in Genetic Retinal Diseases. , 2017, Investigative ophthalmology & visual science.

[15]  P. Neven,et al.  Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Christoph Steinbeck,et al.  ChEBI in 2016: Improved services and an expanding collection of metabolites , 2015, Nucleic Acids Res..

[17]  G. Peters,et al.  ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. , 2005, Cancer research.

[18]  Wenwen Jiang,et al.  The Potential Drug–Drug Interactions of Ginkgolide B Mediated by Renal Transporters , 2015, Phytotherapy research : PTR.

[19]  S. Zeng,et al.  Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin , 2016, Science Translational Medicine.

[20]  Tony Tse,et al.  ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials , 2016, Annals of Internal Medicine.

[21]  B. Walker,et al.  ABCC1 confers tissue-specific sensitivity to cortisol versus corticosterone: A rationale for safer glucocorticoid replacement therapy , 2016, Science Translational Medicine.

[22]  Sean R. Davis,et al.  NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..

[23]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[24]  Mei-Juan Tu,et al.  RNA therapy: Are we using the right molecules? , 2019, Pharmacology & therapeutics.

[25]  B. Li,et al.  The SCN1A Mutation Database: Updating Information and Analysis of the Relationships among Genotype, Functional Alteration, and Phenotype , 2015, Human mutation.

[26]  Jinxiu Lei,et al.  Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up‐regulating histone acetylation state , 2018, British journal of pharmacology.

[27]  A. Yu,et al.  Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression , 2018, Acta pharmaceutica Sinica. B.

[28]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[29]  L. Loeb,et al.  The influence of subclonal resistance mutations on targeted cancer therapy , 2016, Nature Reviews Clinical Oncology.

[30]  Deborah A Zarin,et al.  How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider , 2018, British Medical Journal.

[31]  K. Giacomini,et al.  SLC transporters as therapeutic targets: emerging opportunities , 2015, Nature Reviews Drug Discovery.

[32]  Xing Chen,et al.  MicroRNAs and complex diseases: from experimental results to computational models , 2019, Briefings Bioinform..

[33]  Ian T. Paulsen,et al.  TransportDB 2.0: a database for exploring membrane transporters in sequenced genomes from all domains of life , 2016, Nucleic Acids Res..

[34]  K. Brouwer,et al.  Disease‐Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium , 2018, Clinical pharmacology and therapeutics.

[35]  P. Borst,et al.  N-lactoyl-amino acids are ubiquitous metabolites that originate from CNDP2-mediated reverse proteolysis of lactate and amino acids , 2015, Proceedings of the National Academy of Sciences.

[36]  Y. Assaraf,et al.  Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. , 2017, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[37]  Andreas Bender,et al.  Metrabase: a cheminformatics and bioinformatics database for small molecule transporter data analysis and (Q)SAR modeling , 2015, Journal of Cheminformatics.

[38]  M. Avila,et al.  Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene Therapy , 2019, Hepatology.

[39]  Milton H. Saier,et al.  The Transporter Classification Database (TCDB): recent advances , 2015, Nucleic Acids Res..

[40]  F Müller,et al.  Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin , 2016, Clinical pharmacology and therapeutics.

[41]  Zhankui Jia,et al.  Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1 , 2018, Cell & Bioscience.

[42]  S. Zeng,et al.  Regulation of OCT2 transcriptional repression by histone acetylation in renal cell carcinoma , 2019, Epigenetics.

[43]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[44]  Feng Xu,et al.  Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information , 2015, Nucleic Acids Res..

[45]  Wei Wu,et al.  The drug transporter OAT3 (SLC22A8) and endogenous metabolite communication via the gut–liver–kidney axis , 2017, The Journal of Biological Chemistry.

[46]  Bo Li,et al.  NOREVA: normalization and evaluation of MS-based metabolomics data , 2017, Nucleic Acids Res..

[47]  Joshua C. Euteneuer,et al.  Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical Study , 2018, Clinical pharmacology and therapeutics.

[48]  Bhagwat Prasad,et al.  Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood–Brain Barrier Measured by Quantitative Targeted Proteomics , 2019, Clinical pharmacology and therapeutics.

[49]  O. van Tellingen,et al.  Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. , 2015, Molecular pharmaceutics.

[50]  E. Giovannetti,et al.  Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[52]  F. Rodieux,et al.  Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy , 2016, Journal of clinical pharmacology.

[53]  T. Ishikawa,et al.  A New Trend in Personalized Medicine: Rapid Detection of SNPs in Drug Transporter Genes by the SmartAmp Method , 2011, Clinical pharmacology and therapeutics.

[54]  Alasdair J. G. Gray,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY , 2017, Nucleic Acids Res..

[55]  Ke Wang,et al.  Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition☆ , 2017, Advanced drug delivery reviews.

[56]  C. Allis,et al.  Epigenetics: A Landscape Takes Shape , 2007, Cell.

[57]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[58]  Cheng Huang,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. , 2016, Cancer letters.

[59]  P. Marquet,et al.  Endogenous Metabolites‐Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between SLCO1B1 SNPs and Methotrexate Toxicity , 2018, Clinical pharmacology and therapeutics.

[60]  M. Schwab,et al.  The importance of drug transporter characterization to precision medicine , 2017, Expert opinion on drug metabolism & toxicology.

[61]  Robert E. Stobaugh Chemical Abstracts Service Chemical Registry System. 11. Substance-related statistics: update and additions , 1988, J. Chem. Inf. Comput. Sci..

[62]  K. Giacomini,et al.  The UCSF‐FDA TransPortal: A Public Drug Transporter Database , 2012, Clinical pharmacology and therapeutics.

[63]  Julia M. Barbarino,et al.  PharmGKB: A worldwide resource for pharmacogenomic information , 2018, Wiley interdisciplinary reviews. Systems biology and medicine.

[64]  H. Parkinson,et al.  A global map of human gene expression , 2010, Nature Biotechnology.

[65]  Gerhard F. Ecker,et al.  Prediction of drug–ABC-transporter interaction — Recent advances and future challenges☆ , 2015, Advanced drug delivery reviews.

[66]  M. Hediger,et al.  The ABCs of membrane transporters in health and disease (SLC series): Introduction , 2013, Molecular aspects of medicine.

[67]  Saskia Preissner,et al.  The Transformer database: biotransformation of xenobiotics , 2013, Nucleic Acids Res..

[68]  Gang Fu,et al.  PubChem Substance and Compound databases , 2015, Nucleic Acids Res..

[69]  J. Schiller,et al.  The alanine‐serine‐cysteine‐1 (Asc‐1) transporter controls glycine levels in the brain and is required for glycinergic inhibitory transmission , 2015, EMBO reports.

[70]  David S. Goodsell,et al.  RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy , 2018, Nucleic Acids Res..

[71]  Douglas B. Kell,et al.  Implications of endogenous roles of transporters for drug discovery: hitchhiking and metabolite-likeness , 2016, Nature Reviews Drug Discovery.

[72]  Gregory D. Schuler,et al.  Database resources of the National Center for Biotechnology Information: update , 2004, Nucleic acids research.

[73]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[74]  K. Yanagihara,et al.  Methylation status of breast cancer resistance protein detected by methylation‐specific polymerase chain reaction analysis is correlated inversely with its expression in drug‐resistant lung cancer cells , 2008, Cancer.

[75]  Karryn R. Crisamore,et al.  Clinical Pharmacogenomics: Applications in Nephrology. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[76]  T. Aas,et al.  DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response , 2010, Molecular Cancer.

[77]  G. Yi,et al.  HMPAS: Human Membrane Protein Analysis System , 2013, Proteome Science.